- Conditions
- Geographic Atrophy, Age-related Macular Degeneration
- Interventions
- RO7669330, Syfovre™, Izervay™
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Beverly Hills, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1129–1152
of 3,448
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Participants, Primary Sjögren's Syndrome
- Interventions
- BMS-986325, Placebo for BMS-986325
- Biological · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Covina, California
- Conditions
- Coronary Artery Disease, Acute Coronary Syndrome
- Interventions
- Ticagrelor 180mg, Prasugrel 10mg, Ticagrelor 90mg
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma, Mixed Glioma, Recurrent Adult Brain Neoplasm, Recurrent Glioblastoma
- Interventions
- Laboratory Biomarker Analysis, Lapatinib, Lapatinib Ditosylate, Pharmacological Study, Therapeutic Conventional Surgery
- Other · Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 9 more
- Conditions
- Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, Myasthenia Gravis, Generalized
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Tampa, Florida • Chicago, Illinois + 5 more
- Conditions
- Multiple Myeloma
- Interventions
- AZD0305, Elranatamab, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 9
- States / cities
- Duarte, California • Irvine, California • Atlanta, Georgia + 6 more
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- AZD4831, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Hereditary Angioedema Types I and II
- Interventions
- C1-esterase inhibitor - single intravenous dose, C1-esterase inhibitor - subcutaneous low dose, C1-esterase inhibitor - subcutaneous medium dose, C1-esterase inhibitor - subcutaneous high dose
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chevy Chase, Maryland • Cincinnati, Ohio + 2 more
- Conditions
- Heart Decompensation, Acute
- Interventions
- BMS-986231, BMS-986231 Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours
- Interventions
- AZD8701, Durvalumab
- Drug · Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • St Louis, Missouri • Huntersville, North Carolina + 3 more
- Conditions
- VTE Prophylaxis
- Interventions
- Betrixaban
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Atlanta, Georgia • New Orleans, Louisiana + 1 more
- Conditions
- Thrombin Inhibition
- Interventions
- AZD8165
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Acute Coronary Syndrome
- Interventions
- vicagrel Capsules, Clopidogrel Tablets
- Drug
- Lead sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Kansas City, Missouri
- Conditions
- Healthy Participants
- Interventions
- BMS-986322, Rosuvastatin, Metformin, Glucose, Methotrexate, Leucovorin
- Drug · Dietary Supplement
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- PF-06669571, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Hallandale, Florida • Hollywood, Florida + 4 more
- Conditions
- Hodgkins Lymphoma
- Interventions
- Avelumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Neoplasms, Myelogenous Leukemia, Acute
- Interventions
- RO6839921
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • St Louis, Missouri • Charleston, South Carolina
- Conditions
- Pediatric Attention Deficit Hyperactivity Disorder
- Interventions
- Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Colorado Springs, Colorado • Hialeah, Florida + 7 more
- Conditions
- Type 2 Diabetes
- Interventions
- CAT 1004, Placebo
- Drug
- Lead sponsor
- Catabasis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Stargardt Disease-1
- Interventions
- STG-001
- Drug
- Lead sponsor
- Stargazer Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Gainesville, Florida • Portland, Oregon + 2 more
- Conditions
- Safety and Tolerability
- Interventions
- Experimental drug: ESK-001, Placebo
- Drug · Other
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Myotonic Dystrophy Type 1 (DM1)
- Interventions
- VX-670, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- San Carlos, California • Gainesville, Florida • Fairway, Kansas + 5 more
- Conditions
- Advanced Solid Tumor
- Interventions
- MSC2015103B
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Detroit, Michigan
- Conditions
- Osteoarthritis
- Interventions
- AGG-523 (Aggrecanase Inhibitor)
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Newton, Massachusetts • Winchester, Massachusetts + 1 more